

BAB 5

KESIMPULAN DAN SARAN

5.1 Kesimpulan

Berdasarkan hasil penelitian dari simulasi dinamika kompleks FKBP12-*Rapamycin* pada konsentrasi garam fisiologis yang dilakukan selama 400 ns, maka dapat disimpulkan bahwa :

1. Simulasi dinamika kompleks yang dilakukan selama 400 ns menghasilkan nilai rata-rata dari perhitungan RMSD untuk semua atom protein 0,1506 nm dan atom tulang belakang 0,0812 nm.
2. Hasil nilai rata-rata dari perhitungan RMSF untuk semua atom protein 0,1021 nm atom tulang belakang 0,0537 nm.
3. Interaksi ikatan hidrogen yang terbentuk selama waktu simulasi 400 ns yaitu pada residu I56, Y82, D37, E54, Q53.
4. Interaksi ikatan hidrofobik antara residu W59 dengan gugus pipekolil dengan ligan *rapamycin*, stabil dengan jarak rata-rata yang dihasilkan 0,4571 nm

5.2 Saran

Pada penelitian simulasi dinamika kompleks FKBP12-*Rapamycin* pada konsentrasi garam fisiologis dapat dilanjutkan dengan perhitungan energi bebas.

DAFTAR PUSTAKA

- Abraham, M. J., Van der Spoel, D., Lindahl E., dan Hess, B. 2018, GROMACS User Manual version 2018. 2, www.gromacs.org.
- Allen, M.P. and Tildesley, D.J. 1987, *Computer Simulation of Liquid*, Oxford Science Publication. New York.
- Aldeghi, M., Heifetz, A., Bodkin, M.J., Knapp, S. and Biggin, P.C. 2015, Accurate Calculation of The Absolute Free Energy of Binding for Drug Molecules, *Chemical Science*, **7(1)**: 207–218.
- Bussi, G., Donadio, D. and Parrinello, M. 2008, Canonical Sampling through Velocity-Rescaling, *The Journal of Chemical Physics*, **126(1)**: 014101-1– 014101-7.
- Bogunia, M. and Makowski, M. 2020, Influence of ionic strength on hydrophobic interactions in water: dependence on solute size and shape. *The Journal of Physical Chemistry B*, **124(46)**, 10326-10336.
- Chen, D., Oezguen, N., Urvil, P., Ferguson, C., Dann, S. M., & Savidge, T. C. 2016, Regulation of protein-ligand binding affinity by hydrogen bond pairing. *Science advances*, **2(3)**, e1501240.
- Darden, T., York, D. and Pedersen, L. 1993, Particle mesh Ewald: An N - log(N) method for Ewald sums in large systems, *The Journal of Chemical Physics*, **98(12)**:10089-10092.
- de Freitas, R. F., & Schapira, M. 2017, A systematic analysis of atomic protein–ligand interactions in the PDB. *Medchemcomm*, **8(10)**, 1970-1981.
- Frenkel, D., & Smit, B. 2002, *Understanding molecular simulation: From algorithms to Application* **Vol.1**, Academic Press. San Diego.
- Hess, B., Bekker, H., Berendsen, H.J.C. and Fraaije, J.G.E.M. 1997, LINCS: A Linear Constraint Solver for Molecular Simulations, *Journal of Computational Chemistry*, **18**: 1463–1472.
- Jorgensen W.L., Chandrasekhar J., Madura J.D., Impey R.W., Klein, M.L. 1983, Comparison of simple potential functions for simulating liquid water, *Journal of Chemical Physics*, **79**:926-935.
- Humphrey, W., Dalke, A., and Schulten, K., 1996, VMD: visual molecular dynamics, *Journal of Molecular Graphics*, **14**:33-38

- Hollingsworth, S.A. and Dror, R.O. 2019, Molecular Dynamics Simulation for All, *Neuron*, **99(6)**: 1129-1143.
- Holtje, H. D., Sippl, W., Rognan, D., and Folkers, G., 2008, *Molecular Modeling: Basic Principle and Applications*, ed.3rd, WILEY-VCH Verlag GmbH & Co. KGaA, Germany, 16-18.
- Hospital, A., Goñi, J. R., Orozco, M. & Gelpí, J. L. 2015, Molecular dynamics simulations: advances and applications. *Advances and Applications in Bioinformatics and Chemistry*, **8**, 37-47.
- Kang, C.B., Ye, H., Paganon, S.D., and Yoon, H.S. 2008. FKBP Family Proteins: Immunophilins with Versatile Biological Functions . *Neurosignals*, **16**: 318-325.
- Kolos, J.M., Voll, A.M., Bauder, M., and Hausch, F. 2018. FKBP Ligands where we are and where to go. *Frontiers in Pharmacology*, **9**:1-25
- Liu, Y., Yang, F., Zou, S., & Qu, L. 2019, Rapamycin: A Bacteria-Derived Immunosuppressant That Has Anti-atherosclerotic Effects and Its Clinical Application. *Frontiers in Pharmacology*, **9**: 1-15
- Li, J., Kim, S. G. & Blenis, J. 2014. Rapamycin: One Drug, Many Effects, *Cell Metabolism*, **19**, 373-379.
- Lokken, I. Q., Rusch, C. A., Kastnes, M. H., Kolos, J. M., Jatzlau, J., Hella, H., Holien, T.
- 2023, FKBP12 is a major regulator of ALK2 activity in multiple myeloma cells. *Cell Communication and Signaling*, page 2-16.
- Lindorff-Larsen, K., Piana, S., Palmo, K., Maragakis, P., Klepeis, J. L., Dror, R. O., and Shaw, D. E. 2010, Improved side-chain torsion potentials for the Amber ff99SB protein force field, *Proteins: Structure, Function and Bioinformatics*. **78**:1950-1958.
- Mobley, D.L., Bayly, C.I., Cooper, M.D. and Dill, K.A. 2009, Predictions of Hydration Free Energies from All-Atom Molecular Dynamics Simulations, *The Journal of Physical Chemistry B*, **113(14)**: 4533-4537.
- Neveu, E., Popov, P., Hoffmann, A., Migliosi, A., Besseron, X., Danoy, G., Grudin, S. 2018, RapidRMSD: Rapid determination of RMSDs corresponding to motions of flexible molecules, *Bioinformatics*, **34(16)**: 2757-2765.
- Patodia, S. 2014, Molecular Dynamics Simulation of Proteins: A Brief

Overview. *Journal of Physical Chemistry & Biophysics*, **4(6)**.

- Panwar, V., Singh, A., Bhatt, M., Tonk, R. K., Azizov, S., Raza, A. S., Sengupta, S., Kumar, D., & Garg, M. 2023, Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease. In *Signal Transduction and Targeted Therapy*, **8(1)**. Springer Nature.
- Rasch, J., Theuerkorn, M., Unal, C., Heinsohn, N., Tran, S., Fischer, G., Weiwad, M. and Steinert, M. 2015, Novel Cycloheximide Derivatives Targeting The Moonlighting Protein Mip Exhibit Specific Antimicrobial Activity Against *Legionella pneumophila*, *Bioengineering and Biotechnology*, **3**: 1-8
- Tong, M., and Jianhg, Y. 2015, FK506-Binding Proteins and Their Diverse Functions, *Curr Mol Pharmacol*, **9(1)**: hal 1-3.
- Widjajakusuma, E.C., Frederica, M., Kaweono, K., Shea, A., Jawa, G.D.S.L., Kelan, Y.A., Indah, A., nisavia, F.A., Simatupang, M.Y.Br., Fildzahdina, dan Setiyoningsih, D.V. 2022, Studi Perbandingan Sifat Struktur dan DinamikaBentuk Apo dan Holodari FKBP12 dan Mipdengan Menggunakan Simulasi Dinamika Molekul, *Journal Of Pharmacy Science and Practice*, **9(1)**: 1-6